Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients

被引：0
|
作者：
Gervasini, G.
García-Martín, E.
Ladero, J. M.
Pizarro, R.
Sastre, J.
Martínez, C.
García, M.
Díaz-Rubio, M.
Agúndez, J. A. G.
机构：
[1] Univ Extremadura, Dept Pharmacol & Psychiat, E-06071 Badajoz, Spain
[2] Univ Extremadura, Dept Biochem & Mol Biol & Genet, E-06071 Badajoz, Spain
[3] Univ Complutense Madrid, Hosp Clin Carlos, Gastroenterol Serv, Madrid, Spain
[4] Univ Complutense Madrid, Hosp Clin Carlos, Serv Oncol, Madrid, Spain
来源：
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY | 2006年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：54 / 54
页数：1
相关论文
共 50 条
  • [41] Effect of genetic polymorphisms in CYP3A4, CYP3A5, and m-TOR on everolimus blood exposure and clinical outcomes in cancer patients
    Bonnet, Stephanie
    Falkowski, Sabrina
    Deppenweiler, Marine
    Monchaud, Caroline
    Arnion, Helene
    Picard, Nicolas
    Woillard, Jean-Baptiste
    PHARMACOGENOMICS JOURNAL, 2020, 20 (05): : 647 - 654
  • [42] Effect of genetic polymorphisms in CYP3A4, CYP3A5, and m-TOR on everolimus blood exposure and clinical outcomes in cancer patients
    Stéphanie Bonnet
    Sabrina Falkowski
    Marine Deppenweiler
    Caroline Monchaud
    Hélène Arnion
    Nicolas Picard
    Jean-Baptiste Woillard
    The Pharmacogenomics Journal, 2020, 20 : 647 - 654
  • [43] Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism
    A. B. Sanchez Spitman
    D. J. A. R. Moes
    H. Gelderblom
    V. O. Dezentje
    J.J. Swen
    H. J. Guchelaar
    European Journal of Clinical Pharmacology, 2017, 73 : 1589 - 1598
  • [44] Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism
    Spitman, A. B. Sanchez
    Moes, D. J. A. R.
    Gelderblom, H.
    Dezentje, V. O.
    Swen, J. J.
    Guchelaar, H. J.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 73 (12) : 1589 - 1598
  • [45] Influence of both receptor and donor's CYP3A5 and CYP3A4 genotype in tacrolimus metabolism in liver transplant patients
    Prieto, J. L. Rubio
    Macher, H. C.
    Gomez-Bravo, M. A.
    De Veas-Silva, J. L. Garcia
    Suarez-Artacho, G.
    Rodriguez-Rodriguez, A.
    Sanchez-Pozo, C.
    Guerrero-Montavez, J. M.
    Rubio-Calvo, A.
    CLINICA CHIMICA ACTA, 2024, 558
  • [46] IMPACT OF CYP3A5, CYP3A4, AND ABCB1 GENOTYPES ON TACROLIMUS DOSING AND MONITORING IN LIVER TRANSPLANT PATIENTS
    Ladd, Alexandra
    Pahim, Isabella Angeli
    Warren, Curtis
    Duarte, Sergio
    Zarrinpar, Ali
    HEPATOLOGY, 2022, 76 : S1284 - S1285
  • [47] Genotyping and phenotyping CYP3A4\CYP3A5: no association with antiplatelet effect of clopidogrel
    K. B. Mirzaev
    K. I. Samsonova
    P. P. Potapov
    D. A. Andreev
    E. A. Grishina
    K. A. Ryzhikova
    D. A. Sychev
    Molecular Biology Reports, 2019, 46 : 4195 - 4199
  • [48] Genotyping and phenotyping CYP3A4\CYP3A5: no association with antiplatelet effect of clopidogrel
    Mirzaev, K. B.
    Samsonova, K., I
    Potapov, P. P.
    Andreev, D. A.
    Grishina, E. A.
    Ryzhikova, K. A.
    Sychev, D. A.
    MOLECULAR BIOLOGY REPORTS, 2019, 46 (04) : 4195 - 4199
  • [49] Differential Regulation of CYP3A4 and CYP3A5 and its Implication in Drug Discovery
    Lolodi, Ogheneochukome
    Wang, Yue-Ming
    Wright, William C.
    Chen, Taosheng
    CURRENT DRUG METABOLISM, 2017, 18 (12) : 1095 - 1105
  • [50] Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans
    Santos, A
    Zanetta, S
    Cresteil, T
    Deroussent, A
    Pein, F
    Raymond, E
    Vernillet, L
    Risse, ML
    Boige, V
    Gouyette, A
    Vassal, G
    CLINICAL CANCER RESEARCH, 2000, 6 (05) : 2012 - 2020
12345